Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
63 hedge funds and large institutions have $19.9M invested in Nymox Pharmaceutical Corp in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 8 closing their positions.
813% more call options, than puts
Call options by funds: $621K | Put options by funds: $68K
214% more capital invested
Capital invested by funds: $6.32M → $19.9M (+$13.6M)
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
34% more funds holding
Funds holding: 47 → 63 (+16)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.53M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.29M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$769K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$999K |
| 2 |
Millennium Management
New York
|
-$909K |
| 3 |
Goldman Sachs
New York
|
-$433K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$156K |
| 5 |
Renaissance Technologies
New York
|
-$143K |
NYMX Hedge Fund Activity: Q2 2020 in Review
63 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2020, worth a combined $19.9M — up 214% from $6.32M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NYMX positions and 8 closed out — a net gain of 16 holders — while 12 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $5.53M. The largest seller was Susquehanna International Group, cutting an estimated $999K.
- 63 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2020, up from 47 in Q1 2020.
- Funds reported $19.9M of Nymox Pharmaceutical Corp stock for Q2 2020, up 214% quarter-over-quarter.
- 24 funds opened new Nymox Pharmaceutical Corp positions in Q2 2020 and 8 closed out, a net change of +16 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2020 was BlackRock, an estimated $5.53M added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2020 was Susquehanna International Group, an estimated $999K sold.
Based on aggregated 13F filings for Q2 2020.